U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H37N5O8
Molecular Weight 451.5151
Optical Activity UNSPECIFIED
Defined Stereocenters 13 / 13
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIBEKACIN

SMILES

[H][C@@]2(O[C@H]1O[C@H](CN)CC[C@H]1N)[C@@H](N)C[C@@H](N)[C@]([H])(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O

InChI

InChIKey=JJCQSGDBDPYCEO-XVZSLQNASA-N
InChI=1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1

HIDE SMILES / InChI

Description

Dibekacin is a semisynthetic aminoglycoside antibiotic useful in the treatment of severe gram-negative bacterial infections. The drug is marketed in Japan.

Originator

Approval Year

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
DIBEKACIN MEIJI

PubMed

Sample Use Guides

In Vivo Use Guide
3 mg/kg/day in two intramuscular doses for ten days or 100 mg administered by intravenous drip infusion for 2 hours, twice in a day for 3 - 10 days.
Route of Administration: Other
In Vitro Use Guide
Minimum inhibitory concentrations of Dibekacin were tested against such strains as: S. aureus (max 0.78 mcg/ml), S. epidermidis (0.78 mcg/ml), Micrococcus flavus and Micrococcus luteus (6.25 mcg/ml), Bacillus anthracis (0.39 mcg/ml), B. subtilis (< 0.2 mcg/ml), B. cereus (1.56 mcg/ml), E. coli (0.2 - 100 mcg/ml), Pseudomonas aeruginosa (< 0.2 mcg/ml), P. aeruginosa (1.56 - 100 mcg/ml), Serratia sp. 4 (0.78 mcg/ml), Klebsiella pneumoniae PCI602 (0.39 mcg/ml).